Compared with Sep 23, 2026
Final monthly edition
PEPTIDEBENCHMARK MARKET INTELLIGENCE
September 2026
Peptide Price Index
Data through Sep 30, 2026INDEX VALUE117.20-8.9% 28 days
Baseline = 100 on Jun 3, 2026
Compared with Sep 2, 2026
Current lanes with at least three vendors
2,654 vendor observations
MARKET BREADTH
Most tracked medians moved lower
Movement is based on each peptide’s median effective price per milligram, with ±0.5% treated as approximately flat.
39down
17flat
5up
28-DAY MOVERS
The largest changes in median effective $/mg
These are market-lane medians—not a single vendor’s promotion or a claim about completed transactions.
Largest decreases
01Retatrutide16 vendors · $5.61/mg-26.1%02Tirzepatide15 vendors · $3.15/mg-23.2%03Semaglutide12 vendors · $5.85/mg-21.8%04AHK-CU21 vendors · $0.4965/mg-21.1%05FOXO4-DRI22 vendors · $12.44/mg-19.7%06Gonadorelin6 vendors · $9.22/mg-18.1%07SLU-PP-33214 vendors · $10.71/mg-17.6%08Oxytocin39 vendors · $6.30/mg-16.0%Largest increases
01Mazdutide10 vendors · $9.45/mg+12.2%02Follistatin 3445 vendors · $138.99/mg+11.1%03PEG-MGF11 vendors · $19.50/mg+5.7%04Adipotide5 vendors · $13.30/mg+2.8%05TB-50094 vendors · $6.30/mg+2.6%06Thymalin13 vendors · $4.99/mg+0.4%07VIP45 vendors · $6.39/mg+0.0%NEW OBSERVED LOWS
Median prices at a new tracked low
Requires at least 14 qualifying observations and three current vendors. Gaps are not interpolated.
No qualifying new median lows
The absence of a new low is itself retained with this edition; PB does not force a headline when the data does not support one.
MARKET DEPTH
The most broadly priced peptide lanes
Vendor and offer counts help readers distinguish broad market signals from thinner listings.
| Peptide | Vendors | Offers | Median effective / mg | Current low / mg | 28 day |
|---|---|---|---|---|---|
| GHK-Cu ↗ | 114 | 225 | $0.6221 | $0.1980 | -4.3% |
| BPC-157 ↗ | 114 | 223 | $5.20 | $0.7470 | -3.7% |
| MOTS-c ↗ | 112 | 238 | $3.76 | $0.7470 | -5.6% |
| Tesamorelin ↗ | 103 | 189 | $6.56 | $2.03 | -6.2% |
| Ipamorelin ↗ | 100 | 142 | $5.45 | $0.7920 | -2.7% |
| DSIP ↗ | 95 | 127 | $5.40 | $0.8640 | 0.0% |
| TB-500 ↗ | 94 | 157 | $6.30 | $1.71 | +2.6% |
| Semax ↗ | 94 | 131 | $4.00 | $0.8190 | -9.2% |
| KPV ↗ | 94 | 118 | $4.50 | $0.7470 | -7.0% |
| NAD+ ↗ | 93 | 173 | $0.1105 | $0.0400 | -2.8% |
| Selank ↗ | 93 | 121 | $4.40 | $0.8190 | -0.1% |
| PT-141 ↗ | 90 | 109 | $4.00 | $0.7470 | -4.8% |
METHODOLOGY & CITATION
What this report measures—and what it does not
Every edition carries its construction and coverage snapshot so later citations are interpreted against the data available at publication.
Tracked listing prices
Median effective USD per milligram across exact-comparability offers, using the discount rules recorded with each pricing snapshot.
Fixed-cohort index
Equal-weighted fixed cohort. Each eligible peptide is normalized to 100 at its first observation; daily index values average available normalized medians and require at least 70% cohort coverage.
Coverage limits
This is a tracked-listing index, not a transaction-price index. Vendor mix, availability, quantities, discounts, and catalog coverage can change over time.
SUGGESTED CITATION
PeptideBenchmark. “September 2026 Peptide Price Index Report.” Data through Sep 30, 2026. https://peptidebenchmark.com/prices/reports/2026-09/